Cargando…
Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor
Vascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor mod...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842763/ https://www.ncbi.nlm.nih.gov/pubmed/35001886 http://dx.doi.org/10.3233/ISB-210235 |